SCHEMBL2651925

SCHEMBL2651925

COC(=O)c1ccc(Cl)nc1.CON(C)C(=O)c1ccc(Cl)nc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
L3MBTL1 Q9Y468 5/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.47
NAPRT Q6XQN6 1/20 0.46
RAB9A P51151 2/20 0.45
MAPT P10636 1/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158186 0.93 NAPRT (0.53) SMN1; SMN2POLBPKML3MBTL1GAA
SCHEMBL29552438 0.86 MAPK1 (0.65) MAPK1SMN1; SMN2POLBPKML3MBTL1
SCHEMBL64640 0.86 MAPK1 (0.65) MAPK1SMN1; SMN2POLBPKML3MBTL1
SCHEMBL29776105 0.85 MAPK1 (0.62) MAPK1SMN1; SMN2POLBPKML3MBTL1
SCHEMBL20241211 0.85 MAPK1 (0.62) MAPK1SMN1; SMN2POLBPKML3MBTL1
SCHEMBL3456483 0.81 MAPK1 (0.68) MAPK1L3MBTL1KDM4ERAB9AMAPT
SCHEMBL2660622 0.78 HSD17B3 (0.43) POLBPKML3MBTL1NAPRTRAB9A
SCHEMBL1765450 0.78 MLYCD (0.56) MAPK1SMN1; SMN2L3MBTL1KDM4EGAA
SCHEMBL31606802 0.76 NAPRT (0.60) SMN1; SMN2POLBPKML3MBTL1GAA
SCHEMBL333999 0.76 NAPRT (0.60) SMN1; SMN2POLBPKML3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758859-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 EP disclosed
WO-2005118542-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-15 WO disclosed